Ipsen to Buy Biopharmaceutical Company Epizyme for USD 247 Million
The restructuring of French manufacturer Ipsen has progressed with a takeover agreement for US competitor Epizyme and its cancer drug Tazverik in a deal for slightly less than USD 250 million. Ipsen is proposing USD 1.45 per share for Epizyme, valuing the US company at roughly USD 247 million, and is also promising a contingent value right (CVR) payment of up to USD 1 per share if Tazverik (tazemetostat) meets specific development and sales milestones. The acquisition comes shortly after Ipsen revealed plans to sell its consumer health business for roughly €350 million, leaving the company as a pure...
